Use Able AI chat for product recommendations

TNC/Tenascin-C Polyclonal antibody

TNC/Tenascin-C Polyclonal Antibody for WB, IHC, IP, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, IHC, IP, ELISA

Tenascin, TNC, Glioma-associated-extracellular matrix antigen, GMEM, GP 150 225

Formulation:  PBS, Azide, Glycerol
PBS, Azide, Glycerol
Conjugate:  Unconjugated
Unconjugated
Size/Concentration: 
SKU: 

-/ -

Freight/Packing: -

Quantity

Please visit your regions distributor:

Able AI
Able AI
What's the best dilution for TNC/Tenascin-C in ?

Tested Applications

Positive WB detected inU-87 MG cells
Positive IP detected inU-87 MG cells
Positive IHC detected inhuman liver cancer tissue, human breast cancer tissue, human lung cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:1000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochemistry (IHC)IHC : 1:500-1:2000
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

27789-1-AP targets TNC/Tenascin-C in WB, IHC, IP, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen

CatNo: Ag27122

Product name: Recombinant human TNC protein

Source: e coli.-derived, PGEX-4T

Tag: GST

Domain: 23-200 aa of BC151843

Sequence: GVLKKVIRHKRQSGVNATLPEENQPVVFNHVYNIKLPVGSQCSVDLESASGEKDLAPPSEPSESFQEHTVDGENQIVFTHRINIPRRACGCAAAPDVKELLSRLEELENLVSSLREQCTAGAGCCLQPATGRLDTRPFCSGRGNFSTEGCGCVCEPGWKGPNCSEPECPGNCHLRGRC

Predict reactive species
Full Name tenascin C
Calculated Molecular Weight 2201 aa, 241 kDa
Observed Molecular Weight210-350 kDa
GenBank Accession NumberBC151843
Gene Symbol Tenascin C
Gene ID (NCBI) 3371
RRIDAB_2918131
Conjugate Unconjugated
FormLiquid
Purification MethodAntigen affinity purification
UNIPROT IDP24821
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol, pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Tenascin-C (TNC) is a large hexameric extracellular matrix glycoprotein of the tenascin family (PMID: 21818551). It is a multimodular protein containing multiple epidermal growth factor (EGF)-like repeats and fibronectin type III (FN III) domains (PMID: 1719530). Tenascin-C is highly expressed during embryonic development, particularly in the developing central nervous system, around motile cells and at epithelial-mesenchymal interaction sites (PMID: 25738825). In adult tissues, the expression and the distribution of TNC are typically limited under normal physiological conditions. It is upregulated during injury, inflammation, regeneration, and cancer (PMID: 7694605; 25120494). Tenascin-C is a diverse protein that can produce different functions including regulating cell adhesion, migration and proliferation. In normal esophageal tissue, only one isoform of Tenascin-C (210 kDa) was identified, whereas at least three isoforms (210 kDa, 250 kDa, and 350 kDa) were found in esophageal cancer tissue(PMID: 26731558). It is also reported that tenascin-C exists as two isoforms of approximately 160 kDa and 280 kDa in both healthy and RA patient samples(PMID: 38077374).

Protocols

Product Specific Protocols
IHC protocol for TNC/Tenascin-C antibody 27789-1-APDownload protocol
IP protocol for TNC/Tenascin-C antibody 27789-1-APDownload protocol
WB protocol for TNC/Tenascin-C antibody 27789-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

What published studies show

The TNC/Tenascin-C Polyclonal antibody (Cat# 27789-1-AP) has 1 total citation. The cited publication appeared in Chin Med (Impact Factor 7.4), published in January 2025. The research field is oncology, specifically investigating how Aidi injection inhibits migration and invasion of gefitinib-resistant lung adenocarcinoma cells via the PLAT/FAK/AKT pathway. The antibody was used in Western Blot (WB) with human samples.

SpeciesApplicationTitle
humanWB

Chin Med

Aidi injection inhibits the migration and invasion of gefitinib-resistant lung adenocarcinoma cells by regulating the PLAT/FAK/AKT pathway

Authors - Jingyuan Zhang
Loading...
||
New chat

Able™

正在加载,请稍候...